40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

This study is comparing two radiation doses for the low-risk target area in stage II nasopharyngeal cancer patients who have responded very well to initial chemotherapy and immunotherapy. Researchers hope to find out if a lower radiation dose gives equally good outcomes with fewer side effects. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with stage II nasopharyngeal cancer confirmed by biopsy - After 3 cycles of induction chemotherapy (including immunotherapy), your tumor has responded (complete or partial response confirmed by imaging) - Your Epstein-Barr virus (EBV) DNA levels have dropped to undetectable - Your KPS health performance score is 70 or above - Your blood counts and liver and kidney function are within normal ranges **You may NOT be eligible if...** - Your cancer has returned or spread to distant organs - You are pregnant or breastfeeding - You have not responded adequately to initial chemotherapy - You have a history of another malignancy or other conditions that may interfere with treatment Talk to your doctor to see if this trial is right for you.